Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tevogen Bio Holdings Inc. (TVGN : NSDQ)
 
 • Company Description   
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers. Tevogen Bio Holdings Inc., formerly known as SEMPER PAR ACQ, is based in Warren, New Jersey.

Number of Employees: 18

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.88 Daily Weekly Monthly
20 Day Moving Average: 506,690 shares
Shares Outstanding: 196.71 (millions)
Market Capitalization: $173.83 (millions)
Beta: -0.78
52 Week High: $3.09
52 Week Low: $0.26
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.83% -11.45%
12 Week -26.36% -33.14%
Year To Date -14.20% -23.40%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
15 INDEPENDENCE BOULEVARD SUITE 410
-
WARREN,NJ 07059
USA
ph: 877-838-6436
fax: -
ir@tevogen.com https://tevogen.com
 
 • General Corporate Information   
Officers
Dr. Ryan Saadi - Chief Executive Officer; Chairperson and Director
Kirti Desai - Chief Financial Officer
Jeffrey Feike - Director
Keow Lin Goh - Director
Curtis Patton - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 88165K101
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/18/25
Share - Related Items
Shares Outstanding: 196.71
Most Recent Split Date: (:1)
Beta: -0.78
Market Capitalization: $173.83 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/18/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -775.49
03/31/25 - -934.56
12/31/24 - -380.67
Current Ratio
06/30/25 - 0.26
03/31/25 - 0.35
12/31/24 - 0.26
Quick Ratio
06/30/25 - 0.26
03/31/25 - 0.35
12/31/24 - 0.26
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -0.09
03/31/25 - -0.09
12/31/24 - -0.09
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©